Lenacapavir HIV Prevention: Approval and Access...

By Rene Pretorius

February 21, 2025

Gilead Sciences has submitted marketing authorization applications to the European Medicines Agency (EMA) for lenacapavir HIV prevention, a twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV prevention. This ...
Journavx Pain Management: FDA Approves New Non-Opioid Treatment for Acute Pain
Engineered Heart Muscle Allografts Show Promise in Heart Repair
Genetic Testing in South Africa
PEPFAR Funding Pause Threatens Global HIV Progress
Healthcare at Home: CMC Dubai’s Innovative Program
Promising Results of Personalized Cancer Vaccine in Renal Cell Carcinoma
Cost-Effective CML Treatment in South Africa
Trends in Endometrial Cancer Mortality
Boosting HPV Vaccine Uptake Among Young People Post-Pandemic
Cervical Cancer Burden: Global Trends and Future Projections
FDA Grants Datopotamab Deruxtecan Approval for HR-Positive Breast Cancer Trea...
MPA Meningioma Risk: Key Insights and Implications